Latest Breaking News On - Clinical research program - Page 8 : comparemela.com

Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress

/PRNewswire/ Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today.

Comunidad autonoma de catalunaTim mccarthySecurities exchangeClinical research programRelmada therapeutics incEuropean college of neuropsychopharmacologyPrnewswire relmada therapeutics incEuropean collegeRelmada therapeuticsPrivate securities litigation reform actSecurities actSecurities exchange actHealth care amp hospitalsMedical pharmaceuticalsClinical trials amp medical discoveriesTrade show news

Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder

Patients newly treated with REL-1017 for up to one year experienced rapid, clinically meaningful, and sustained improvements in depressive symptoms and associated functional impairmentLong-term.

Cedric ogormanTim mccarthySecurities exchangeClinical research programRelmada therapeutics incPrnewswire relmada therapeutics incCorporate communicationsMajor depressive disorderCedrico gormanChief medical officerSustained substantial improvementClinical responseBoth rapidClinical remissionScale also showed clinical improvementClinical global impression

Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder

/PRNewswire/ Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today.

Cedric ogormanTim mccarthyRelmada therapeutics incPrnewswire relmada therapeutics incClinical research programSecurities exchangeMajor depressive disorderCedrico gormanChief medicalRelight phaseRelmada therapeuticsPrivate securities litigation reform actSecurities actSecurities exchange act

Study Shows New Approach to Target Deadly Form of Prostate Cancer

Study Shows New Approach to Target Deadly Form of Prostate Cancer
goodmenproject.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from goodmenproject.com Daily Mail and Mail on Sunday newspapers.

United statesPeters nelsonAnna megdellOliviaa swaimIlsa colemanColm morrisseyJoshij alumkalWilliamk storckChao zhangArchana sehrawatKaran bediAaron udagerZhi duanJoshi alumkalXiao ming wangDiana flores

New approach to target a deadly form of prostate cancer

New approach to target a deadly form of prostate cancer
sciencedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sciencedaily.com Daily Mail and Mail on Sunday newspapers.

Joshi alumkalAnbarasu kumaraswamyAlumkal laboratoryClinical research program at rogelWicha family professorClinical research program